Lyra therapeutics reports first quarter 2024 financial results and provides corporate update

-- phase 3 results from enlighten 1 trial of lyr-210 in chronic rhinosinusitis (crs) expected in may -- -- phase 3 results from enlighten 1 trial of lyr-210 in chronic rhinosinusitis (crs) expected in may --
LYRA Ratings Summary
LYRA Quant Ranking